特异性免疫治疗变应性鼻炎的疗效及安全性临床分析

Evaluation of efficacy and safety of specific immunotherapyfor patients with allergic rhinitis

摘要:

目的 评价特异性免疫治疗变应性鼻炎的疗效及安全性。方法 对65例变应性鼻炎患者进行1~3年特异性免疫治疗后，通过患者的症状评估进行临床疗效及安全性的分析。结果 65例患者中3例中途退出（治疗未满1年），其余62例经过1~3年特异性免疫治疗，多数患者症状均有不同程度好转。治疗结束时显效25例（40.32%），有效18例（29.03%），无效19例（30.65%），总有效率69.35%。 其中25例治疗满1年，显效7例（28%），有效7例（28%），无效11例（44%），有效率56%； 21例满2年，显效10例（47.62%），有效5例（23.81%），无效6例（28.57%），有效率71.43%； 16例满3年，显效8例（50%），有效6例（37.5%），无效2例（12.5%），有效率87.5%。所有患者均未发生严重不良反应。结论 特异性免疫治疗对于变应原明确的变应性鼻炎患者，是一种有效、安全可靠的治疗方法。 

Abstract:

Objective To evaluate the efficacy and safety of specific immunotherapy for patients with allergic rhinitis. Methods 65 patients with allergic rhinitis received the specific immunotherapy for 1~3 years. Symptom scores were used for evaluating the efficacy and safety of immunotherapy. Results Of 65 patients, 3 quitted. Majority of the other 62 patients got better after treatment. 25 patients (40.32%) got obvious improvement, 18 (29.03%) were effective, and 19 (30.65%) were ineffective. The total effective rate was 69.35%. Of 25 patients received treatment for one year, 7 (28%) were obvious effective, 7 were (28%) effective, with an effective rate of 56%. Of 21 patients received treatment for two years, 10 (47.62%) were obvious effective, 5 (23.81%) were effective, with an effective rate of 71.43%. Of 16 patients received treatment for three years, 8 (50%) were obvious effective, 6 (37.5%) were effective, with an effective rate of 87.5%.No serious adverse reaction occurred. Conclusion Specific immunotherapy is an effective and safe treatment method for patients with allergic rhinitis.